Viewing Study NCT06551506

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-26 @ 2:43 PM
Ignite Modification Date: 2026-03-17 @ 5:43 PM
Study NCT ID: NCT06551506
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-12-22
First Post: 2024-08-09
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: The Immunology and Safety of Maternal RSV Vaccination (ABRYSVO), Infant Nirsevimab (BEYFORTUS) Immunization, or Both Products
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Respiratory Syncytial Virus Infection View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Nirsevimab View
None Respiratory syncytial virus View
None RSV View
None RSVpreF View
None ABRYSVO View
None BEYFORTUS View
None Immunology View
None Infants View